Loading...
Derniers dépôts
-
Rishma Amarsy, Sandra Fournier, David Trystram, Catherine Monteil, Xavier Raynaud, et al.. Decrease of hospital- and community-acquired bloodstream infections due to Streptococcus pneumoniae and Streptococcus pyogenes during the first year of the COVID-19 pandemic: A time-series analysis in Paris region. American Journal of Infection Control, 2022, 51 (4), pp.475-477. ⟨10.1016/j.ajic.2022.09.002⟩. ⟨hal-03868704⟩
-
Nadia Nathan, Blandine Prevost, Sidonie Lambert, Aurélie Schnuriger, Harriet Corvol. Severe Acute Respiratory Syndrome Coronavirus 2 Variant Delta Infects All 6 Siblings but Spares Comirnaty (BNT162b2, BioNTech/Pfizer)-Vaccinated Parents. Journal of Infectious Diseases, 2021, 224 (11), pp.1984-1986. ⟨10.1093/infdis/jiab410⟩. ⟨hal-03827740⟩
-
Marine Maurel, Francisco Pozo, Gloria Pérez‐gimeno, Silke Buda, Noémie Sève, et al.. Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study. Influenza and Other Respiratory Viruses, 2024, 18 (1), pp.e13243. ⟨10.1111/irv.13243⟩. ⟨pasteur-04646591⟩
-
Marine Maurel, Jennifer Howard, Esther Kissling, Francisco Pozo, Gloria Pérez-Gimeno, et al.. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. Eurosurveillance, 2024, 29 (8), ⟨10.2807/1560-7917.es.2024.29.8.2400089⟩. ⟨pasteur-04646586⟩
-
Charlotte Lanièce Delaunay, Iván Martínez-Baz, Noémie Sève, Lisa Domegan, Clara Mazagatos, et al.. COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022. Eurosurveillance, 2024, 29 (13), pp.2300403. ⟨10.2807/1560-7917.es.2024.29.13.2300403⟩. ⟨pasteur-04644962⟩
-
Marie Herbein, Susana Barbosa, Ophélie Collet, Olfa Khalfallah, Marie Navarro, et al.. Cord serum cytokines at birth and children's trajectories of mood dysregulation symptoms from 3 to 8 years: The EDEN birth cohort. Brain, Behavior & Immunity - Health, 2024, 38, pp.100768. ⟨10.1016/j.bbih.2024.100768⟩. ⟨hal-04642219⟩
-
Anders Boyd, Mariam El Dani, Roula Ajrouche, Vanessa Demontant, Justine Cheval, et al.. Gut microbiome diversity and composition in individuals with and without extended-spectrum β-lactamase-Producing enterobacterales carriage: a matched case-control study in infectious diseases department. Clinical Microbiology and Infection, In press, ⟨10.1016/j.cmi.2024.03.016⟩. ⟨hal-04539691⟩
-
Célina Pognonec, Zidane Dirhoussi, Nicolas Cury, Marie Moreau, Charlotte Billard, et al.. External validation of Glasgow-Blatchford, modified Glasgow-Blatchford and CANUKA scores to identify low-risk patients with upper gastrointestinal bleeding in emergency departments: a retrospective cohort study. Emergency Medicine Journal, 2023, 40 (6), pp.451-457. ⟨10.1136/emermed-2022-213052⟩. ⟨hal-04630504⟩
-
Paul Loubet, Jean-Daniel Lelievre, Alexis Francois, Elisabeth Botelho-Nevers, Christian Chidiac, et al.. Humoral response after mRNA COVID-19 primary vaccination and single booster dose in people living with HIV compared to controls: a French nationwide multicenter cohort study - ANRS0001s COV-POPART. International Journal of Infectious Diseases, 2024, 146, pp.107110. ⟨10.1016/j.ijid.2024.107110⟩. ⟨hal-04627501⟩
-
Makiko Omura, Samuele Cortese, Marion Bailhache, Marie Navarro, Maria Melchior, et al.. Associations between symptoms of attention-deficit hyperactivity disorder, socioeconomic status and asthma in children. NPJ Mental Health Research , 2024, 3 (1), pp.22. ⟨10.1038/s44184-024-00064-z⟩. ⟨hal-04620426⟩
-
Marie Pouquet, Dorine Decarreaux, Laura Di Domenico, Chiara Sabbatini, Pol Prévot-Monsacre, et al.. SARS-CoV-2 infection prevalence and associated factors among primary healthcare workers in France after the third COVID-19 wave. Scientific Reports, 2024, 14 (1), pp.5418. ⟨10.1038/s41598-024-55477-9⟩. ⟨hal-04494616⟩
-
Christel Gérardin. Développement d’un outil d’aide à la décision thérapeutique pour quatre maladies rares : le lupus érythémateux, la sclérodermie systémique, la maladie de Takayasu, le syndrome des anti-phospholipides. Médecine humaine et pathologie. Sorbonne Université, 2023. Français. ⟨NNT : 2023SORUS424⟩. ⟨tel-04615710⟩